Sequence variations in the UDP - Glucuronosyltransferase 2B7 (UGT2B7) gene: Identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucoronidation in cancer patients

Pharmacogenomics Journal

Volumn 3, Issue 1, 2003, Pages 17-26

  Holthe, M ^a   Rakvag T N ^a   Klepstad, P ^a,b   Idle, J R ^a   Kaasa, S ^b   Krokan, H E ^a   Skorpen, F ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Morphine; Morphine 3 glucoronide; Morphine 6 glucoronide; UGT

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOFIBRIC ACID; CODEINE; CORTICOSTEROID; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B7; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; UNCLASSIFIED DRUG; VALPROIC ACID; ZIDOVUDINE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER PAIN; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HAPLOTYPE; HUMAN; IN VIVO STUDY; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NORWAY; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLOW RELEASE FORMULATION;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MORPHINE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SEQUENCE ANALYSIS, DNA; TUMOR CELLS, CULTURED; VARIATION (GENETICS);

EID: 0037251316     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500139     Document Type: Article

References (29)

1. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993a; 264: 475-479.
2. Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y (268) and UGT2B7H (268). Drug Metab Dispos 1998; 26: 73-77.
3. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25: 1-4.
4. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, Belanger A. 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 2000; 28: 497-502.
5. Jin CJ, Miners JO, Burchell B, Mackenzie PI. The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. Carcinogenesis 1993b; 14: 2637-2639.
6. Vore M, Montgomery C, Meyers M. Steroid D-ring glucuronides: characterization of a new class of cholestatic agents. Drug Metab Rev 1983; 14: 1005-1019.
7. Worrall S, Dickinson RG. Rat serum albumin modified by diflunisal acyl glucuronide is immunogenic in rats. Life Sci 1995; 56: 1921-1930.
8. Radominska-Pandya A, Little JM, Czernik PJ. Human UDP-glucuronosyl-transferase 2B7. Curr Drug Metab 2001; 2: 283-298.
9. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O et al. Morphine glucuronide to morphine serum ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58: 353-356.
10. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679-685.
11. McQuay HJ, Carroll D, Faura CC, Cavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48: 236-244.
12. Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000; 55: 713-719.
13. Faura CC, Collins SL, Moore RA, McQuay HJ. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998; 74: 43-53.
14. Mentre F, Escolano S, Diquet B, Golmard JL, Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur J Clin Pharmacol 1993; 45: 397-407.
15. Ishii Y, Takami A, Tsuruda K, Kurogi A, Yamada H, Oguri K. Induction of two UDP-glucuronosyltransferase isoforms sensitive to phenobarbital that are involved in morphine glucuronidation: production of isoform-selective antipeptide antibodies toward UGT1.1r and UGT2B1. Drug Metab Dispos 1997; 25: 163-167.
16. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-122.
17. Ermolaeva MD. Synonymous codon usage in bacteria. Curr Issues Mol Biol 2001; 3: 91-97.
18. Smith NG, Eyre-Walker AJ. Why are translationally sub-optimal synonymous codons used in Escherichia coli? Mol Evol 2001; 53: 225-236.
19. Kim CH, Oh Y, Lee TH. Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene 1997; 199: 293-301.
20. André S, Seed B, Eberle J, Schraut W, Bültmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998; 72: 1497-1503.
21. Duret L, Mouchiroud D. Determinants of substitution rates in mammalian genes: expression pattern affects selection intensity but not mutation rate. Mol Biol Evol 2000; 17: 68-74.
22. Ishii Y, Hansen AJ, Mackenzie PI. Octamer transcription factor-1 enhances hepatic nuclear factor-1α-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol 2000; 57: 940-947.
23. Strassburg CP, Kneip S, Topp J, Obermeyer-Straub P, Barut A, Tukey RH et al. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 2000; 275: 36 164-36 171.
24. Jin CJ, Mackenzie PI, Miners JO. The regio- and stereo-selectivity of C19 and C21 hydroxysteroid glucuronidation by UGT2B7 and UGT2B11. Arch Biochem Biophys 1997; 341: 207-211.
25. Toide K, Takahashi Y, Yamazaki H, Terauchi Y, Fujii T, Parkinson A et al. Hepatocyte nuclear factor-1 alpha is a causal factor responsible for inter-individual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human Livers. Drug Metab Dispos 2002; 30: 613-615.
26. Patwardhan RV, Johnson RF, Hoyumpa Jr A, Sheehan JJ, Desmond PV, Wilkinson GR et al. Normal metabolism of morphine in cirrhosis. Gastroenterology 1981; 81: 1006-1011.
27. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate. Dos and don'ts for assessing kidney function. Postgrad Med 2001; 110: 55-62; quiz 11.
28. Bogusz MJ, Maier RD, Driessen S. Morphine, morphine-3-glucuronide, morphine-6-glucuronide, and monoacetylmorphine determined by means of atmospheric pressure chemical ionization-mass spectrometry-liquid chromatography in body fluids of heroin victims. J Anal Toxicol 1997; 21: 346-355.
29. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997; 22: 176-181.